Gynaecologic cancers
PARP-inhibitor maintenance in BRCA/HRD-positive ovarian cancer and immunotherapy in cervical and endometrial cancer.
- Trials
- 1
- Years
- 2018
Sort
- 2018SOLO-1BRCA-mutated ovarianIn 391 patients with newly diagnosed BRCA1/2-mutated advanced ovarian cancer in response to first-line platinum, maintenance olaparib for two years improved progression-free and overall survival compared with placebo.HR 0.3Read →